Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group

Provencio, Mariano; Cruz Mora, M.Á.; Gómez‐Codina, José; Quero Blanco, Cristina; Llanos, Marta; R. García-Arroyo, Francisco; de la Cruz‐Merino, Luis; Gumà Padró, Josep; Ramón Delgado Pérez, Juan; Sánchez, Antonio; Álvarez Cabellos, R.; Rueda, Antonio; the Gotel (Spanish Lymphoma Oncology Group), for

doi:10.3109/10428194.2013.790544

Public

Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group

Published in Leukemia & lymphoma/Leukemia and lymphoma • Apr 11, 2013

Authors:

Mariano Provencio

M.Á. Cruz Mora

José Gómez‐Codina

Abstract

Relapse is the main cause of therapeutic failure in follicular lymphoma (FL). We set out to evaluate the role of consolidation with Yttrium-90 ibritumomab tiuxetan in patients with intermediate- and high-risk FL after four cycles of CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, rit...

Subject

Medicine

International Prognostic Index

Follicular lymphoma

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!